Advertisement

Conference Report: Psychiatric Genomics Consortium Meeting: Pathways to Drugs, London, March 2017

  • Héléna A. Gaspar
    Affiliations
    Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London

    United Kingdom National Institute for Health Research Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London
    Search for articles by this author
  • David A. Collier
    Affiliations
    Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London

    Discovery Neuroscience Research, Eli Lilly and Company, Windlesham, Surrey, United Kingdom
    Search for articles by this author
  • Daniel H. Geschwind
    Affiliations
    Program in Neurogenetics, Department of Neurology and Center for Autism Research and Treatment, Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, California
    Search for articles by this author
  • Cathryn M. Lewis
    Affiliations
    Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London

    United Kingdom National Institute for Health Research Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London
    Search for articles by this author
  • Qingqin Li
    Affiliations
    Neuroscience Therapeutic Area, Janssen Research and Development, Titusville, New Jersey
    Search for articles by this author
  • Bryan L. Roth
    Affiliations
    Department of Pharmacology, Chapel Hill, North Carolina

    National Institute of Mental Health Psychoactive Drug Screening Program, School of Medicine, Chapel Hill, North Carolina

    Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Search for articles by this author
  • Patrick F. Sullivan
    Affiliations
    Department of Genetics, Chapel Hill, North Carolina

    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Search for articles by this author
  • Gerome Breen
    Correspondence
    Address correspondence to Gerome Breen, Ph.D., Institute of Psychiatry, Psychology and Neuroscience, Medical Research Council Social Genetic and Developmental Psychiatry Research Centre, PO82, MRC SGDP, 16 De Crespgny Park Denmark Hill, London, SE5 8AF United Kingdom.
    Affiliations
    Medical Research Council Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London

    United Kingdom National Institute for Health Research Biomedical Research Centre for Mental Health, South London and Maudsley Hospital, London
    Search for articles by this author
Published:February 08, 2018DOI:https://doi.org/10.1016/j.biopsych.2018.01.024
      The Psychiatric Genomics Consortium (PGC) (www.med.unc.edu/pgc) is delivering an increasing flow of discoveries about the fundamental basis of psychiatric disorders. Moving from the discovery of genome-wide association study (GWAS) loci toward delivering new therapeutic approaches is a challenge that requires a new wave of multidisciplinary work and close liaison between academia and industry. The PGC has recently initiated a new research program to deliver “actionable” findings that 1) reveal the fundamental biology of psychiatric disorders, 2) inform clinical practice, and 3) deliver new therapeutic targets. Working with industry will be essential, but there is a lack of a forum to exchange ideas with academia. With the aim of filling this gap, the first PGC Pathways to Drugs industry–academia workshop was held at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London on March 2 and 3, 2017. We review the main advances in the field (

      PGC Meeting: Pathways to Drugs. Abstracts. Available at: https://sites.google.com/view/pgc-pharma-meeting/abstracts. Accessed January 4, 2018.

      ).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. PGC Meeting: Pathways to Drugs. Abstracts. Available at: https://sites.google.com/view/pgc-pharma-meeting/abstracts. Accessed January 4, 2018.

        • Fromer M.
        • Roussos P.
        • Sieberts S.K.
        • Johnson J.S.
        • Kavanagh D.H.
        • Perumal T.
        • et al.
        Gene expression elucidates functional impact of polygenic risk for schizophrenia.
        Nat Neurosci. 2016; 19: 1442-1453
        • Breen G.
        • Li Q.
        • Roth B.L.
        • O’Donnell P.
        • Didriksen M.
        • Dolmetsch R.
        • et al.
        Translating genome-wide association findings into new therapeutics for psychiatry.
        Nat Neurosci. 2016; 19: 1392-1396
        • Duncan L.
        • Yilmaz Z.
        • Gaspar H.
        • Walters R.
        • Goldstein J.
        • Anttila V.
        • et al.
        Significant locus and metabolic genetic correlations revealed in genome-wide association study of anorexia nervosa.
        Am J Psychiatry. 2017; 174: 850-858
        • Sudlow C.
        • Gallacher J.
        • Allen N.
        • Beral V.
        • Burton P.
        • Danesh J.
        • et al.
        UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age.
        PLoS Med. 2015; 12: e1001779
        • Gaspar H.A.
        • Breen G.
        Pathways analyses of schizophrenia GWAS focusing on known and novel drug targets.
        bioRxiv. 2017; ([published online ahead of print Aug 18])
        • Wray N.R.
        • Sullivan P.F.
        • Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
        Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depressive disorder.
        bioRxiv. 2017; ([published online ahead of print Jul 24])
        • Won H.
        • de la Torre-Ubieta L.
        • Stein J.L.
        • Parikshak N.N.
        • Huang J.
        • Opland C.K.
        • et al.
        Chromosome conformation elucidates regulatory relationships in developing human brain.
        Nature. 2016; 538: 523-527
        • Akbarian S.
        • Liu C.
        • Knowles J.A.
        • Vaccarino F.M.
        • Farnham P.J.
        • et al.
        • PsychENCODE Consortium
        The PsychENCODE project.
        Nat Neurosci. 2015; 18: 1707-1712
        • Cai L.
        • Fisher A.L.
        • Huang H.
        • Xie Z.
        CRISPR-mediated genome editing and human diseases.
        Genes Dis. 2016; 3: 244-251